Hims & Hers Health (HIMS) EBITDA Margin (2020 - 2026)

Hims & Hers Health has disclosed EBITDA Margin across 7 years of filings, most recently posting 16.25% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 16.25%, down 2472.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.74% (down 995.0% YoY), and the FY2025 annual result was 5.58%, down 294.0% from the prior year.
• EBITDA Margin came in at 16.25% for Q1 2026 at Hims & Hers Health, down from 3.56% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 18.92% in Q3 2024 to a low of 17.46% in Q2 2022.
• The 5-year median for EBITDA Margin is 0.51% (2023), against an average of 1.51%.
• Across the five-year window, EBITDA Margin jumped 8215 bps in 2022 and tumbled 2472 bps in 2026, its largest moves.
• Hims & Hers Health's EBITDA Margin stood at 6.41% in 2022, then soared by 108 bps to 0.51% in 2023, then jumped by 941 bps to 5.29% in 2024, then tumbled by 33 bps to 3.56% in 2025, then sank by 557 bps to 16.25% in 2026.
• The last three EBITDA Margin figures came in at 16.25% (Q1 2026), 3.56% (Q4 2025), and 2.65% (Q3 2025), per Business Quant data.